Access to Genetic Testing in Underserved Patients With Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Southern California

About this trial

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age > 18 years old

Epithelial ovarian cancer

Exocrine pancreatic cancer

Metastatic or high or very high-risk prostate cancer

Disqualifiers

Patients who cannot provide informed consent

Patients who cannot see, read, or write

Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish

Patients with none of the listed cancer diagnoses and clinical characteristics

Trial design

Design model

Parallel

Treatments tested in this trial

  • Best Practice

    Other intervention

    Receive provider-based genetic counseling

  • Educational Intervention

    Other intervention

    Receive genetics education

  • Electronic Health Record Review

    Other intervention

    Ancillary studies

  • Genetic Counseling

    Other intervention

    Receive provider-based genetic counseling

  • Interview

    Other intervention

    Ancillary studies

  • Survey Administration

    Other intervention

    Ancillary studies

Treatment groups

800 Participants
are divided into 2 treatment groups
Group A: Intervention Phase Arm A (PERLA)Experimental treatment 5 interventions
Group B: Intervention Phase Arm B (usual care)Active comparator 3 interventions

Trial outcomes

Primary outcomes

1

Proportion of participants who receive genetic testing

The proportion of participants who receive genetic testing will be reported.

Time frame
Up to 3 months

Secondary outcomes

1

Patient-reported outcomes

Correlations with patient level factors, such as education, literacy, acculturation, and language will be examined.

Time frame
Up to 3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Southern California

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Northeastern University

Collaborator

Dana-Farber Cancer Institute

Collaborator